Characteristics of the patients at enrolment (full cohort, year 1)
| Characteristic | N=127 |
|---|---|
| Age (years) at enrolment, mean±SD | 66.8±8.6 |
| Female sex, n (%) | 59 (46.5%) |
| Smoking history pack-years, median (IQR) | 47.0 (33.7–60.0) |
| Medication for COPD, n (%) | 127 (100%) |
| Influenza vaccination during previous year, n (%) | 114 (89.8%) |
| Pneumococcal vaccination during previous year, n (%) | 12 (9.4%) |
| COPD status, GOLD stage, n (%) | |
| Mild | 0 (0%) |
| Moderate | 57 (44.9%) |
| Severe | 51 (40.2%) |
| Very severe | 19 (15.0%) |
| BODE index, median (IQR) | 4 (2–6) |
| TLCO predicted/actual (mmol/kPa/min), median (IQR) | 7.9 (7.2–8.8)/4.5 (3.4–5.8) |
| Number of subjects reporting exacerbations in preceding 12 months, n (%) | |
| One exacerbation | 28 (22.0%) |
| Two exacerbations | 37 (29.1%) |
| Three exacerbations | 25 (19.7%) |
| Four or more exacerbations | 37 (29.1%) |
| Number of exacerbations in preceding 12 months, mean±SD/median (IQR) | 3.1±2.3/2 (2–4) |
| Number of exacerbations in preceding 12 months according to severity, mean±SD | |
| Mild | 0.5±1.2 |
| Moderate | 2.3±1.9 |
| Severe | 0.4±0.6 |
| FEV1 after bronchodilator use (% predicted), mean±SD | 46.4±15.2 |
BODE index, body mass index, airflow obstruction, modified Medical Research Council Dyspnoea Scale, exercise capacity index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; N, total number of subjects; TLCO, transfer factor of the lung for carbon monoxide.